European Commission preliminary report says Teva violated antitrust rules
TEVA stock on watch after EU approval for biosimilar to Roche's Lucentis (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals Sterile Manufacturing Facility, Ulm - Pharmaceutical Technology
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ELYBYTG4QZMUJPXRYDKAVNSTAI.jpg "New branded drugs helping Teva Pharm move closer to growth | Reuters")
New branded drugs helping Teva Pharm move closer to growth | Reuters
Teva said to 'walk away' from settlement talks in US price-fixing lawsuit | The Times of Israel
Giant becomes even bigger: Teva acquires ratiopharm
Teva: Reportedly Planning Thousands of Layoffs in the U.S. | Fortune
Teva reports jump in first-quarter earnings, raises guidance | The Times of Israel
Who raised $175 million and how do you mess up a $2 billion takeover? | Ctech
Fallout from Teva plant closings, global layoffs continues in Israel | Fierce Pharma
Teva to move global HQ to Tel Aviv amid $3B cost-cutting drive | Fierce Pharma
Principle - leveraging the power of brand for Teva
Teva Pharmaceuticals to Cut 25% of Jobs in Huge Reshaping - The New York Times
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Teva Pharmaceuticals Europe - With #ERSCongress 2019 approaching, the Let's Talk Respiratory team want to give you a flavour of things to come. From Q&As, symposiums, and a booth we know you'll
Teva leans on Ajovy and Austedo as revenues sink
What To Do After EU Hits Teva With Antitrust Concerns (NYSE:TEVA) | Seeking Alpha
Exclusive: Teva Set to Win EU Okay for $40.5 Billion Allergan Deal - Sources
Why Europe's drug shortages may get worse | Article | China Daily
Teva to cut 14,000 jobs | Business | Chemistry World
Teva shed 37% of Israel workforce in two years - Globes
Why Europe's drug shortages may get worse | Reuters
Teva concludes $703m women's health products deal with CVC Capital - Pharmaceutical Technology
Anything but Generic: A map for Selling to Teva Pharmaceuticals
Teva: 'Celltrion deal will double biosimilar sales to $600m'
